Seres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment Conference
Seres Therapeutics (Nasdaq: MCRB), a live biotherapeutics company, will participate in the H.C. Wainwright Global Investment Conference in New York City. The company's management will deliver a corporate presentation on September 8, 2025 at 3:00 p.m. ET.
A webcast replay of the presentation will be accessible on the Seres website approximately two hours after the event and will remain available for 21 days.
Seres Therapeutics (Nasdaq: MCRB), azienda di bioterapeutici vivi, parteciperà alla H.C. Wainwright Global Investment Conference a New York. La direzione dell’azienda terrà una presentazione aziendale il 8 settembre 2025 alle 15:00 ET.
Una replica webcast della presentazione sarà disponibile sul sito di Seres circa due ore dopo l’evento e resterà accessibile per 21 giorni.
Seres Therapeutics (Nasdaq: MCRB), una compañía de bioterapéuticos vivos, participará en la H.C. Wainwright Global Investment Conference en Nueva York. La dirección de la compañía ofrecerá una presentación corporativa el 8 de septiembre de 2025 a las 3:00 p.m. ET.
Una repetición en webcast de la presentación estará disponible en el sitio web de Seres aproximadamente dos horas después del evento y permanecerá accesible durante 21 días.
Seres Therapeutics (Nasdaq: MCRB)는 라이브 바이오치료제 기업으로, 뉴욕에서 열리는 H.C. Wainwright Global Investment Conference에 참가합니다. 회사 경영진은 2025년 9월 8일 오후 3시(동부 표준시, ET)에 기업 프레젠테이션을 진행할 예정입니다.
프레젠테이션의 웹캐스트 다시보기는 행사 종료 후 약 두 시간 뒤 Seres 웹사이트에서 제공되며, 21일 동안 시청 가능하게 유지됩니다.
Seres Therapeutics (Nasdaq: MCRB), une société de biothérapeutiques vivantes, participera à la H.C. Wainwright Global Investment Conference à New York. La direction de l’entreprise présentera une conférence d’entreprise le 8 septembre 2025 à 15h00 (ET).
Une rediffusion web de la présentation sera accessible sur le site de Seres environ deux heures après l’événement et restera disponible pendant 21 jours.
Seres Therapeutics (Nasdaq: MCRB), ein Unternehmen für lebende Biotherapeutika, wird an der H.C. Wainwright Global Investment Conference in New York City teilnehmen. Die Unternehmensleitung wird am 8. September 2025 um 15:00 Uhr ET eine Unternehmenspräsentation halten.
Eine Webcast-Wiederholung der Präsentation wird etwa zwei Stunden nach der Veranstaltung auf der Seres-Website verfügbar sein und für 21 Tage abrufbar bleiben.
- None.
- None.
CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will attend the upcoming H.C. Wainwright Global Investment Conference in New York City and will present a company overview at 3:00 p.m. ET on September 8, 2025.
A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. Seres led the successful development and approval of VOWST™, the first FDA-approved orally administered microbiome therapeutic, which was sold to Nestlé Health Science in September 2024. The Company is developing SER-155, which has received Breakthrough Therapy designation for the reduction of bloodstream infections in adults undergoing allo-HSCT and Fast Track designation for reducing the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT, and which has demonstrated a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT. SER-155 and the Company's other pipeline programs are designed to target multiple disease-relevant pathways and are manufactured from standard clonal cell banks via cultivation, rather than from the donor-sourced production process used for VOWST. In addition to allo-HSCT, the Company intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically vulnerable patient populations including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities. For more information, please visit www.serestherapeutics.com.
Investor and Media Contact:
IR@serestherapeutics.com
Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com
FAQ
When is Seres Therapeutics (MCRB) presenting at the H.C. Wainwright Conference?
How long will the MCRB conference presentation webcast be available?
Where can I watch Seres Therapeutics' (MCRB) H.C. Wainwright presentation?
What type of company is Seres Therapeutics (MCRB)?
